Annovis Bio Q1 net loss $0.63/sh; AD Phase 3 85% enrolled; NDA planned early 2027

Annovis Bio, Inc.

Net loss per share $0.63 (vs $0.32 in Q1 2025); R&D spend $16.7M (up from $5.0M).
Cash $14.2M at Mar 31, 2026; $10M April offering not included; 28.5M shares outstanding.
Phase 3 AD trial 85% enrolled, full enrollment on track summer 2026; DSMB safety recommendation positive.
PD OLE study 40% enrolled; NDA for buntanetap symptomatic AD treatment expected early 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annovis Bio, Inc. reported first quarter ended March 31, 2026 results: EPS $0.63 basic and diluted net loss per common share.

Period: first quarter ended March 31, 2026
EPS: $0.63 basic and diluted net loss per common share
Result: reported results

Exact text from the filing

Annovis reported a $0.63 basic and diluted net loss per common share for the three months ended March 31, 2026, compared to a $0.32 basic and diluted net loss per common share for the three months ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-062451

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.